Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents
- PMID: 20884709
- PMCID: PMC3012783
- DOI: 10.3324/haematol.2010.030882
Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents
Abstract
The emergence of oligoclonal bands is associated with a favorable outcome after autologous stem cell transplantation in multiple myeloma. The aim of this study was to determine the prevalence of immunoglobulin oligoclonality in 33 patients with multiple myeloma in complete remission achieved with primary therapy with either cytotoxic agents (n = 18, 54.5%) or new induction regimens incorporating novel drugs (n = 15, 45.4%). Eleven patients (33.3%) developed oligoclonal bands. In the group treated with novel agents, this oligoclonal immune response was observed in 60% (9 of 15) of the patients versus only 11.1% (2 of 18) of those given cytotoxic therapy (P = 0.003). This is the first report showing a different frequency of oligoclonal humoral response in patients in complete remission achieved after conventional cytotoxic therapy versus induction incorporating novel agents. This difference could be due to a higher antitumor effect associated with the use of novel drugs, a stronger immune reconstitution, or both.
Comment in
-
Lack of correlation between emergence of an abnormal protein band or of oligoclonal bands and survival in patients with multiple myeloma achieving complete remission following autologous stem cell transplantation.Haematologica. 2011 Apr;96(4):e29. doi: 10.3324/haematol.2011.041509. Haematologica. 2011. PMID: 21454876 Free PMC article. No abstract available.
Similar articles
-
Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition.Blood. 2009 Dec 3;114(24):4954-6. doi: 10.1182/blood-2009-06-224832. Epub 2009 Oct 1. Blood. 2009. PMID: 19797521
-
Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution.Haematologica. 2013 Jul;98(7):1142-6. doi: 10.3324/haematol.2013.084350. Epub 2013 May 3. Haematologica. 2013. PMID: 23645688 Free PMC article.
-
Oligoclonal reconstitution masquerading as myeloma relapse.Ann Hematol. 2013 Jun;92(6):847-8. doi: 10.1007/s00277-012-1624-x. Epub 2012 Nov 14. Ann Hematol. 2013. PMID: 23150202 No abstract available.
-
Role of bone marrow transplantation in the disease pathway of myeloma.J Natl Compr Canc Netw. 2007 Feb;5(2):163-9. doi: 10.6004/jnccn.2007.0016. J Natl Compr Canc Netw. 2007. PMID: 17335685 Review.
-
[IgE-κ type multiple myeloma achieving complete response with novel agents].Rinsho Ketsueki. 2017;58(11):2232-2237. doi: 10.11406/rinketsu.58.2232. Rinsho Ketsueki. 2017. PMID: 29212974 Review. Japanese.
Cited by
-
Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry.Blood Cancer J. 2024 Mar 18;14(1):50. doi: 10.1038/s41408-024-00995-y. Blood Cancer J. 2024. PMID: 38499538 Free PMC article.
-
The incidence and clinical significance of monoclonal and oligoclonal protein bands in multiple myeloma patients after BCMA-CAR-T cell therapy: A retrospective study based on LEGEND-2.Hemasphere. 2024 Nov 19;8(11):e70054. doi: 10.1002/hem3.70054. eCollection 2024 Nov. Hemasphere. 2024. PMID: 39564538 Free PMC article.
-
Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma.Cancers (Basel). 2019 Dec 18;12(1):12. doi: 10.3390/cancers12010012. Cancers (Basel). 2019. PMID: 31861479 Free PMC article.
-
Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma.Haematologica. 2014 Dec;99(12):1846-53. doi: 10.3324/haematol.2014.111104. Epub 2014 Sep 5. Haematologica. 2014. PMID: 25193963 Free PMC article. Clinical Trial.
-
Audit of the Prevalence of Noncorrelation of Immunofixation with Protein Electrophoresis and Serum Free Light Chain Assays in Multiple Myeloma in a Tertiary Cancer Care Center.Indian J Clin Biochem. 2021 Jul;36(3):353-359. doi: 10.1007/s12291-020-00924-3. Epub 2020 Sep 15. Indian J Clin Biochem. 2021. PMID: 34220011 Free PMC article.
References
-
- Zent CS, Wilson CS, Tricot G, Jagannath S, Siegel D, Desikan KR, et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood. 1998;91(9):3518–23. - PubMed
-
- Hovenga S, de Wolf JT, Guikema JE, Klip H, Smit JW, Smit Sibinga CT, et al. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Bone Marrow Transplant. 2000;25(7):723–8. - PubMed
-
- Fernandez de Larrea C, Cibeira MT, Elena M, Arostegui JI, Rosiñol L, Rovira M, et al. Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition. Blood. 2009;114(24):4954–6. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical